Veru Inc. Reports Promising First Quarter Advances
Veru Inc. (NASDAQ: VERU) has made waves with the recent reporting of its fiscal 2025 first quarter financial results alongside positive developments in its clinical programs. The company has exhibited sustainable growth and innovations in its drug offerings, reinforcing its commitment to tackling cardiometabolic diseases. A key highlight is the positive topline results for the Phase 2b QUALITY study concerning the novel combination of enobosarm and semaglutide (also known as Wegovy). This pivotal study met its primary endpoint, demonstrating effective preservation of lean mass while promoting fat loss and improving physical function.
Significant Clinical Study Results
On January 27, 2025, Veru announced the positive topline results from its Phase 2b QUALITY study, a meticulously designed trial to assess the efficacy of enobosarm in overweight and obese older adults (>60 years) receiving semaglutide. The study was a multicenter, double-blind, placebo-controlled trial, making it the first to evaluate a muscle preservation agent in this patient demographic. The results showed that patients treated with enobosarm alongside semaglutide experienced a statistically significant reduction in lean mass loss compared to those treated with semaglutide alone.
Study Details and Outcomes
The participants receiving the 3mg dosage of enobosarm combined with semaglutide showcased over a 99% mean relative reduction in lean mass loss, providing a robust foundation for future studies. Evaluating fat mass against the placebo group, the results highlighted a significant dose-dependent fat loss, with the 6mg group achieving a 46% greater fat loss than the placebo counterpart.
Future Expectations and Strategic Plans
Excitingly, an Independent Data Monitoring Committee recently reviewed the unblinded safety data of the Phase 2b QUALITY study and voiced their support for continuing the extension study as planned. Topline results from this Phase 2b extension maintenance study, aimed at reducing fat regain after halting GLP-1 receptor agonist therapy, are expected to emerge in the second quarter of fiscal 2025.
Expansion into Cardiometabolic Indications
In addition to their findings from enobosarm, Veru has announced its decision to advance the development of sabizabulin, targeting inflammation in atherosclerotic cardiovascular disease—a significant unmet need given the high mortality rate associated with coronary artery disease (CAD). The company is keen on evaluating the effectiveness of sabizabulin as a potential treatment option for this widespread condition.
Financial Overview for First Quarter
Veru's financial snapshot from the first quarter of fiscal 2025 reveals notable progress. Research and development expenses soared to $5.7 million, up from $1.7 million the previous year, indicating a strong investment in innovative therapies. Meanwhile, selling, general, and administrative expenses showed a decrease to $5.2 million from $6.7 million, highlighting operational efficiencies.
Cash Position and Future Investments
As of December 31, 2024, the company's cash, cash equivalents, and restricted cash stood at $26.6 million, up from $24.9 million at the quarter's end in September 2024. This solid financial footing is expected to support ongoing clinical trials and expansions into new therapeutic areas.
Investor and Media Communication
The outlook for Veru remains encouraging as the company continues to navigate pivotal trials and explore new opportunities. Investors and interested parties can keep abreast of developments via the company's investor relations. Veru is poised for future growth and is excited about bringing its innovative treatments to market. For more information, contact:
Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: veruinvestor@verupharma.com
Frequently Asked Questions
What are the primary findings of the Phase 2b QUALITY study?
The study demonstrated that enobosarm combined with semaglutide significantly preserved lean body mass and led to greater fat loss in older patients compared to semaglutide alone.
How will Veru use the proceeds from the FC2 business sale?
Estimated proceeds from the sale will enhance cash reserves to support ongoing clinical trials and research initiatives at Veru.
What is sabizabulin, and why is it significant?
Sabizabulin is a novel oral broad anti-inflammatory agent being explored as a treatment for inflammation in atherosclerotic CAD, addressing a significant medical need.
What is the future outlook for Veru’s enobosarm product?
Veru plans to request an end-of-Phase-2 meeting with the FDA to discuss the regulatory pathway based on the successful results from the Phase 2b study.
How does Veru plan to enhance the safety and efficacy of its treatments?
Veru is committed to developing innovative drug formulations and thorough clinical trials to ensure the safety and efficacy of its therapies while minimizing adverse effects.
